Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. Weil-Hillman G, Fisch P, Prieve AF, Sosman JA, Hank JA, Sondel PM (1989) Cancer Res 49: 3680-8 Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Weil-Hillman G, Voss SD, Fisch P, Schell K, Hank JA, Sosman JA, Sugamura K, Sondel PM (1990) Cancer Res 50: 2683-91 Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer. Higano CS, Vogelzang NJ, Sosman JA, Feng A, Caron D, Small EJ (2004) Clin Cancer Res 10: 1219-25 Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ (2013) Clin Cancer Res 19: 2240-7 A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Sosman JA, Fisher SG, Kefer C, Fisher RI, Ellis TM (1994) Ann Oncol 5: 447-52 P75 neurotrophin receptor regulates expression of neural cell adhesion molecule 1. Mirnics ZK, Yan C, Portugal C, Kim TW, Saragovi HU, Sisodia SS, Mirnics K, Schor NF (2005) Neurobiol Dis 20: 969-85 A phase II trial of interleukin-2 in myelodysplastic syndromes. Nand S, Stock W, Stiff P, Sosman J, Martone B, Radvany R (1998) Br J Haematol 101: 205-7
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.